X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - DRUGS.COM - Pharma Industry News - 09/07/2024 15:54

Intensity-Modulated Radiotherapy Recommended for Locally Advanced Lung Cancer

TUESDAY, July 9, 2024 -- Intensity-modulated radiotherapy (IMRT) is recommended for locally advanced non-small cell lung cancer (NSCLC) and appears to have good long-term outcomes, according to a study published online June 27 in JAMA...

Articles similaires

Sorry! Image not available at this time

Surgery for Early-Stage NSCLC Yields Similar Outcomes in Octogenarians, Younger Patients

drugs.com - 10/Apr 15:04

FRIDAY, April 10, 2026 -- Surgical treatment for early-stage non-small cell lung cancer (NSCLC) is associated with similarly favorable safety and...

Sorry! Image not available at this time

Surgery for Early-Stage NSCLC Yields Similar Outcomes in Octogenarians, Younger Patients

drugs.com - 10/Apr 15:04

FRIDAY, April 10, 2026 -- Surgical treatment for early-stage non-small cell lung cancer (NSCLC) is associated with similarly favorable safety and...

Sorry! Image not available at this time

Transdermal Estradiol Patches Noninferior to LHRH Agonists for Prostate Cancer

drugs.com - 10/Apr 15:04

FRIDAY, April 10, 2026 -- For men with locally advanced prostate cancer, transdermal estradiol (tE2) patches are noninferior to luteinizing...

Sorry! Image not available at this time

Transdermal Estradiol Patches Noninferior to LHRH Agonists for Prostate Cancer

drugs.com - 10/Apr 15:04

FRIDAY, April 10, 2026 -- For men with locally advanced prostate cancer, transdermal estradiol (tE2) patches are noninferior to luteinizing...

Sorry! Image not available at this time

Salubris Biotherapeutics Presents Phase 1/2 Dose Escalation and Expansion Cohort Data for JK06, 5T4-Targeted Antibody Drug Conjugate, at the American Association for Cancer Research Annual Meeting

wn.com - 17/Apr 23:26

10 confirmed partial responses (PRs) among 38 response-evaluable non-small cell lung cancer (NSCLC) patients (ORR 26%), including three of seven...

Sorry! Image not available at this time

Salubris Biotherapeutics Presents Phase 1/2 Dose Escalation and Expansion Cohort Data for JK06, 5T4-Targeted Antibody Drug Conjugate, at the American Association for Cancer Research Annual Meeting

wn.com - 17/Apr 23:26

10 confirmed partial responses (PRs) among 38 response-evaluable non-small cell lung cancer (NSCLC) patients (ORR 26%), including three of seven...

Sorry! Image not available at this time

Clinician Notes for Sickle Cell Patients Often Include High Number of Negative Descriptors

drugs.com - 16/Apr 15:04

THURSDAY, April 16, 2026 -- Patients with sickle cell disease (SCD) have more negative descriptors than Black patients without SCD and those with...

Sorry! Image not available at this time

Clinician Notes for Sickle Cell Patients Often Include High Number of Negative Descriptors

drugs.com - 16/Apr 15:04

THURSDAY, April 16, 2026 -- Patients with sickle cell disease (SCD) have more negative descriptors than Black patients without SCD and those with...

Sorry! Image not available at this time

Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026

wn.com - 17/Apr 23:26

Encouraging early results catalyze continued investigation in the MATISSE Phase 2 study evaluating IPH5201, a first-in-class anti-CD39 monoclonal...

Sorry! Image not available at this time

Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting

mangaloremirror.com - 18:54

REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing...

Les derniers communiqués